PUBLIC COMPANY
save$ONCBeOne Medicines Ltd.
$ONC411.29-1.26%Basel, CHupdated 14h ago
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
community read0 votes
🐶 often sniffed alongside
top 7pipeline
8
marketed
1
phase 3
1
catalysts ytd
5
approvals ytd
0
recalls ytd
0
Pipeline(8)
pipeline depth8 products
1Phase 12Phase 21Phase 31Marketed2Unknown1pre_registration
Marketed
zanubrutinib
Membranous Glomerulonephritis
Tyrosine-protein kinase BTK
Phase 3Tevimbra
Small-Cell Lung Cancer
Programmed cell death protein 1
Phase 2BGB-16673
Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2surzebiclimab
Recurrent Head And Neck Squamous Cell Carcinoma
Phase 1BGBB-2033
Metastatic Hepatocellular Carcinoma (HCC)
drugBG-89894
drugBGC-0979
pre_registrationsonrotoclax
Mantle Cell Lymphoma
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →🐶 Hiring Signal
News
- BeOne, Hengrui top list of China’s most powerful drugmakersA new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.stat · 1d ago
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 6d ago
- Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think soFor executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…fiercebiotech · 10d ago
- RevMed’s Rasonque shatters analyst estimates with $198M quarterPent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.biospace · 11d ago
- With MFN now embedded in pharma, execs see little impact from Democrats’ blue waveSpeaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.biospace · 12d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 13d ago
- Nurix drops one BTK degrader as momentum builds behind Roche-partnered optionNurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.fiercebiotech · 1mo ago
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- DPHARM: How to address the clinical trial enrollment crisis?Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.fiercebiotech · 2mo ago
- Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…biospace · 2mo ago
Data sources
last refreshed 40m ago
Found something off?
comments(0)
5-min edit window · permanent after that